The world's first in vitro diagnostic (IVD) test for predicting kidney disease progression. It effectively predicts the risk of rapid renal function decline in patients with diabetic kidney disease. The test is non-invasive, urine-based, and highly accurate, providing precise and effective predictiv...
Manufactured by
Zhubei City, Hsinchu, Taiwan
Bio Preventive Medicine (BPM) is an innovative clinical-staged biotech company, focusing on early detection and prevention of diseases specialty of those high value added molecular diagnostic product. Started from an ITRI (a Taiwanese national lab and global top 100 innovator) spin-off in 2014 to launch the first product " DNlite ", BPM is now growing into a leading company in innovative renal diagnostic solution, with a GMP (Taiwan FDA) /QMS accredited plant & ISO 17025 accredited Lab Facilities at Hsinchu, Taiwan. The company has demonstrated excellence with domain expertise in translational research and IVD development, brought up a new revolutionary page of precision medicine. DNlite, an ELISA based non-invasive urinary test for monitoring the progression of Diabetic Nephropathy, is an effective tool for screening, detecting and monitoring kidney complications in diabetes. Unlike the current standard test (known as eGFR and UACR) can only detect the disease once it's already present, DNlite predicts kidney function loss years in advance. It can be also applied in CKD, AKD, and Kidney Transplant. In addition to diabetic nephropathy, the proprietary technology of BPM also include biomarker-based diagnostic technology for other chronic diseases and oncology. At Bio Preventive Medicine Corp. , we hold significant intellectual property rights for our clinically validated biomarker product and are very interested in pursuing business partnerships via licensing, co-development, clinical research projects, or product distribution.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
TradeWinds Consulting Inc.
Taiwan · 1 relevant product
Anhui Huibang Biological Engineering Co., Ltd.
China · 9 relevant products
Micropoint Bioscience, Inc.
United States · 2 relevant products
BioPorto Diagnostics
United States · 5 relevant products
CareforU Co., Ltd.
South Korea · 1 relevant product
AEHEALTH Limited
China · 1 relevant product
Analyticon Biotechnologies GmbH
Germany · 2 relevant products
Nova Biomedical Corporation
United States · 1 relevant product
Lansion Biotechnology Co., Ltd.
China · 2 relevant products
HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD
China · 1 relevant product
65 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →3 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 105 closest product alternatives
TradeWinds Consulting Inc. · Taiwan
A urinary ELISA kit for detecting specific biomarkers and post-translational modifications to assess diabetic kidney disease progression. DNlite-IVD103 predicts kidney function decline in diabetes patients over 1-2 years, enabling early intervention. The test holds CE IVD mark and Malaysia MDA regulatory approvals.
Anhui Huibang Biological Engineering Co., Ltd. · China
An in vitro detection system for early diagnosis indicators of diabetic nephropathy in human urine. It features multi-channel composite detection with selected indicator combinations including urinary microalbumin, urinary haptoglobin, and urinary creatinine as an internal standard. The system uses dry biochemistry and immunology methods, allows random urine self-testing without invasive procedures, and supports home-based testing with mobile device image upload for server analysis and professional feedback.
Anhui Huibang Biological Engineering Co., Ltd. · China
In vitro diagnostic system for early detection of diabetic kidney disease through urine analysis. Combines dry-reagent technology with multi-channel detection of key biomarkers including urine microalbumin, uromodulin, and creatinine. Enables both clinical laboratory quantitative analysis and point-of-care home testing with mobile result upload and remote interpretation.
Anhui Huibang Biological Engineering Co., Ltd. · China
An invention patent product (ZL 2017 1 0507989.9) for in vitro detection of early diagnostic markers of diabetic kidney disease in human urine. It is a Class II urine detection product using dry biochemistry and immunology methods with multi-channel composite detection. The system detects urine microalbumin, urine haptoglobin, and urine creatinine as internal standard. It features non-invasive random urine self-testing, stable dry reagents, and can be used for home self-testing with mobile device result upload for server-based analysis and professional feedback.
Anhui Huibang Biological Engineering Co., Ltd. · China
A diagnostic reagent kit designed for early diagnosis of diabetic nephropathy. The kit enables early detection and assessment of kidney disease in diabetic patients.
Micropoint Bioscience, Inc. · United States
A microfluidic-based diagnostic test system for diabetes and kidney injury monitoring with lab-level accuracy. Provides point-of-care testing capabilities for diabetes and renal function assessment.
BioPorto Diagnostics · United States
CE-marked in vitro diagnostic test for early detection of acute kidney injury using the NGAL biomarker. Identifies kidney damage earlier than traditional serum creatinine and urine output methods, enabling timely clinical intervention.
CareforU Co., Ltd. · South Korea
Comprehensive in vitro diagnostic testing panel for assessment of kidney function and detection of renal disease. Includes measurement of relevant biomarkers and clinical parameters.
Anhui Huibang Biological Engineering Co., Ltd. · China
Urine detection test strip for early diagnosis of diabetic nephropathy using dry biochemistry and immunological methods. Measures urine microalbumin, urine haptoglobin, and urine creatinine as standardized indicators. Multi-channel composite detection enables precise quantification in clinical settings or home-based screening.
Anhui Huibang Biological Engineering Co., Ltd. · China
In vitro diagnostic test for combined detection of inflammatory and kidney disease markers in urine samples. Utilizes dry-phase reagent technology with multi-channel analysis to detect urinary microalbumin, uromodulin, and creatinine for early diabetic nephropathy diagnosis. Enables both laboratory quantitative testing and point-of-care self-testing with mobile image capture and server-based result analysis.
BioPorto Diagnostics · United States
An FDA-cleared biomarker test for pediatric acute kidney injury risk assessment based on NGAL detection. It is the first FDA-cleared biomarker test for this indication and is available for use on the Cobas c 501 clinical chemistry analyzer through Roche Diagnostics.
BioPorto Diagnostics · United States
FDA-cleared biomarker test for pediatric acute kidney injury risk assessment. Available for use on Roche Diagnostics Cobas c 501 clinical chemistry analyzer to rapidly identify kidney damage in pediatric patients.
93 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products